Video

Dr. Lenz Explores KRAS/NRAS Mutations in Colorectal Cancer

Heinz-Josef Lenz, MD, from the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of KRAS and NRAS mutations in metastatic colorectal cancer.

Heinz-Josef Lenz, MD, the co-director of the Colorectal Center and GI Oncology Program at the USC Norris Comprehensive Cancer Center, discusses the potential predictive impact of traditionally wild-type KRAS and NRAS mutations in metastatic colorectal cancer (mCRC).

To date, Lenz notes, KRAS testing has been restricted to codons 12 and 13; however, the phase II PEAK trial suggests that testing should now include codons 61, 117, and 146. This trial examined the affects of non-traditional (wild-type) activating KRAS and NRAS mutations on the clinical activity of EGFR inhibitors. Overall, Lenz suggests, testing for these additional codons could help screen 20% more patients with mCRC for treatment with EGFR inhibitors.

PEAK is a phase II trial and these data have not yet been validated, Lenz points out. As such, analyses will be applied to the FIRE-3 and the CALGB 8045 trials to see if these findings can be further validated. If they can, this could have a dramatic impact on how patients with mCRC are screened and treated, Lenz believes. This method could help to more accurately select patients who will benefit from EGFR inhibitors.

<<<

View more from the World GI Congress

Related Videos
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Priya U. Kumthekar, MD
David Schiff, MD
Timothy Gershon, MD, PhD
Jordan Hansford, MD
J. Bradley Elder, MD